Schroeder, Barbara
Vander Steen, Travis
Espinoza, Ingrid
Venkatapoorna, Chandra M. Kurapaty
Hu, Zeng
Silva, Fernando Martín http://orcid.org/0000-0002-3496-9093
Regan, Kevin
Cuyàs, Elisabet http://orcid.org/0000-0001-5353-440X
Meng, X. Wei
Verdura, Sara
Arbusà, Aina
Schneider, Paula A.
Flatten, Karen S.
Kemble, George
Montero, Joan http://orcid.org/0000-0002-9192-4836
Kaufmann, Scott H. http://orcid.org/0000-0002-4900-7145
Menendez, Javier A. http://orcid.org/0000-0001-8733-4561
Lupu, Ruth http://orcid.org/0000-0002-5564-3172
Funding for this research was provided by:
Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (CP20/00003)
Ministerio de Economía y Competitividad (RYC-2015-18357)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA166741, R01 CA116623)
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (PID2019-10455GB-I00)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Defense (BC151072, BC151072P1)
Article History
Received: 10 March 2021
Revised: 12 September 2021
Accepted: 24 September 2021
First Online: 21 October 2021
Competing interests
: George Kemble is the Chief Executive Officer and Chief Scientific Officer at Sagimet Biosciences (formerly known as 3-V Biosciences). Joan Montero reports previous consulting for Vivid Biosciences and Oncoheroes Biosciences, current collaboration with AstraZeneca, and an unpaid board membership for The Society for Functional Precision Medicine. All the other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: Animal studies were conducted in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the Mayo Institutional Animal Care and Use Committee (IACUC).